Comparison of different therapeutic strategies in hypertension:: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach

被引:99
作者
Mourad, JJ
Waeber, B
Zannad, F
Laville, M
Duru, G
Andréjak, M
机构
[1] Avicenne Hosp, Dept Internal Med, Bobigny, France
[2] Univ Hosp, Div Clin Pathophysiol, Lausanne, Switzerland
[3] Univ Hosp, CIC, INSERM, Nancy, France
[4] Univ Hosp, Div Nephrol, Lyon, France
[5] CNRS, Lyon, France
[6] Div Clin Pharmacol, Amiens, France
关键词
fixed-dose combination; sequential monotherapy; stepped-care treatment; perindopril; indapamide; losartan; hydrochlorothiazide; atenolol; amlodipine; valsartan;
D O I
10.1097/00004872-200412000-00021
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective To compare the efficacy and the tolerability of three different strategies in the treatment of hypertension (low-dose combination, sequential monotherapy and stepped-care). Design Hypertensive patients were randomized to a 9-month treatment with the aim to lower blood pressure below 140/90 mmHg. Treatment adjustments were allowed at months 3 and 6. The study was discontinued for patients with normal blood pressure at month 6. In the 'low-dose combination' group, perindopril (2 mg) and indapamide (0.625 mg) were first administered with the possibility to increase the doses in two steps up to respectively, 4 and 1.25 mg. In the 'sequential monotherapy' group, the treatment was initiated with atenolol (50 mg), replaced if necessary by losartan (50 mg), and then by amlodipine (5 mg). In the 'stepped-care' group, valsartan, was given first at a 40 mg dose, then at a 80 mg dose, to be co-administered finally if needed with hydrochlorothiazide, 12.5 mg. All study tablets were encapsulated to conceal their identity and had to be taken once a day. Patients Patients with uncomplicated essential hypertension were recruited (n = 180 in the 'low-dose combination' group, n = 176 in the 'sequential monotherapy' group and n = 177 in the 'stepped-care' group). Results The percentage of patients having achieved the target blood pressure was significantly greater in the 'low-dose combination' group (62%) than in the 'sequential monotherapy'(49%, P=0.02) and the 'stepped-care' group (47%, P=0.005). The percentage of patients having normalized their blood pressure without experiencing drug-related adverse events was also significantly higher in the 'low-dose combination' group (56%) than in the 'sequential monotherapy' (42%, P=0.002) and the 'stepped-care' group (42%, P=0.004). Conclusions A first line management of hypertension based on a low-dose combination of perindopril and indapamide allows the normalization of blood pressure in significantly more patients than a 'sequential monotherapy' strategy involving atenolol, losartan and amlodipine, and a 'stepped-care' strategy involving valsartan and hydrochlorothiazide. These better blood pressure results were not obtained at the expense of a worsening of tolerability. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:2379 / 2386
页数:8
相关论文
共 23 条
[1]   2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension [J].
Afridi, I ;
Canny, J ;
Yao, CH ;
Christensen, B ;
Cooper, RS ;
Kadiri, S ;
Hill, S ;
Kaplan, N ;
Kuschnir, E ;
Lexchin, J ;
Mendis, S ;
Poulter, N ;
Psaty, BM ;
Rahn, KH ;
Sheps, SG ;
Whitworth, J ;
Yach, D ;
Bengoa, R ;
Ramsay, L ;
Kaplan, N ;
Mendis, S ;
Poulter, N ;
Whitworth, J .
JOURNAL OF HYPERTENSION, 2003, 21 (11) :1983-1992
[2]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[3]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[4]  
BRUNNER HR, 1990, J HYPERTENS, V8, P3, DOI 10.1097/00004872-199001000-00002
[5]   Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients [J].
Chalmers, J ;
Castaigne, A ;
Morgan, T ;
Chastang, C .
JOURNAL OF HYPERTENSION, 2000, 18 (03) :327-337
[6]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[7]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[8]   Optimisation of antihypertensive treatment by crossover rotation of four major classes [J].
Dickerson, JEC ;
Hingorani, AD ;
Ashby, MJ ;
Palmer, CR ;
Brown, MJ .
LANCET, 1999, 353 (9169) :2008-2013
[9]   Newer approaches to antihypertensive therapy - Use of fixed-dose combination therapy [J].
Epstein, M ;
Bakris, G .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (17) :1969-1978
[10]  
Franklin SS, 2001, CIRCULATION, V103, P1245